Introduction: Pediatric Ear, Nose, and Throat (ENT) infections pose significant challenges world wide, causing discomfort and complications for children. Probiotics have emerged as a potential preventive measurea gainst ENT infections, modulating the gutmicrobiota and immune system. Despite their promise, well-designed clinical trials are needed to evaluate their efficacy. Methods: A randomized, double-blind, placebo-controlled trial was conducted on children aged 3-12 years with recurrent ENT infections. Participants were randomized to receive either probiotics or placebo for 6 months. The primary outcome was the incidence of ENT infections, while secondary outcomes included symptoms everity, duration, and healthcarevisitsrelated to infections. Results: Participants receiving probiotics showed a lower incidence of ENT infections (35%) compared to the placebo group (55%). Probioticsupplementation was associated with shorter durations and lower severity of symptoms, including fever, ear pain, nasal congestion, and throat discomfort. Children in the probiotic group also had fewerhealth care visits related to ENT infections. No significant adverse events were reported in either group. Conclusion: Probiotic supplementation demonstrates efficacy in reducing the incidence, severity, and duration of pediatric ENT infections, with potential implications for healthcare utilization. These findings underscore the importance of probiotics as a preventive measure and highlight the need for future research in this area.

Pediatric Ear, Nose, and Throat (ENT) infections pose significant challenges world wide, causing discomfort and complications for children.